Dichotomy in duration and severity of acute inflammatory responses in humans arising from differentially expressed proresolution pathways

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 19, 2010, Pages 8842-8847

  Morris, Thea ^a   Stables, Melanie ^a   Colville Nash, Paul ^b   Newson, Justine ^a   Bellingan, Geoffrey ^a   De Souza, Patricia M ^c   Gilroy, Derek W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ST HELIER HOSPITAL   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Eicosanoids; Inflammation; Leukocytes

Indexed keywords

ACETYLSALICYLIC ACID; CANTHARIDIN; CHEMOKINE; CYTOKINE; FORMYLPEPTIDE RECEPTOR LIKE 1; LIPOXIN A;

ADULT; ARTICLE; BLISTER; CELL COUNT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INFLAMMATION; MACROPHAGE; MALE; NEUTROPHIL; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; ASPIRIN; HUMANS; INFLAMMATION; LIPOXINS; MALE; MIDDLE AGED; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, LIPOXIN; TIME FACTORS;

RODENTIA;

EID: 77952725991     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1000373107     Document Type: Article

References (42)

1. Gilroy DW, Lawrence T, Perretti M, Rossi AG (2004) Inflammatory resolution: New opportunities for drug discovery. Nat Rev Drug Discov 3:401-416. (Pubitemid 38618123)
2. Hallett JM, et al. (2008) Novel pharmacological strategies for driving inflammatory cell apoptosis and enhancing the resolution of inflammation. Trends Pharmacol Sci 29:250-257.
3. Serhan CN, Savill J (2005) Resolution of inflammation: The beginning programs the end. Nat Immunol 6:1191-1197.
4. Serhan CN (2002) Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: An update and role in anti-inflammation and pro-resolution. Prostaglandins Other Lipid Mediat 68-69:433-455.
5. Perretti M, et al. (2002) Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat Med 8:1296-1302. (Pubitemid 35373563)
6. Romano M, Serhan CN (1992) Lipoxin generation by permeabilized human platelets. Biochemistry 31:8269-8277.
7. Edenius C, Haeggström J, Lindgren JA (1988) Transcellular conversion of endogenous arachidonic acid to lipoxins in mixed human platelet-granulocyte suspensions. Biochem Biophys Res Commun 157:801-807. (Pubitemid 19021250)
8. Fiore S, Serhan CN (1990) Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulating factor-primed neutrophils. J Exp Med 172:1451-1457. (Pubitemid 20366221)
9. Clària J, Serhan CN (1995) Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA 92:9475-9479.
10. Chiang N, Bermudez EA, Ridker PM, Hurwitz S, Serhan CN (2004) Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci USA 101:15178-15183. (Pubitemid 39391738)
11. Clària J, Lee MH, Serhan CN (1996) Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation. Mol Med 2:583-596. (Pubitemid 26353107)
12. Rajakariar R, et al. (2009) Nonresolving inflammation in gp91phox-/- mice, a model of human chronic granulomatous disease, has lower adenosine and cyclic adenosine 5′-monophosphate. J Immunol 182:3262-3269.
13. Bystrom J, et al. (2008) Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP. Blood 112:4117-4127.
14. Fang Y, Yu S, Braley-Mullen H (2007) Contrasting roles of IFN-gamma in murine models of autoimmune thyroid diseases. Thyroid 17:989-994. (Pubitemid 350071603)
15. Hurst SM, et al. (2001) Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14: 705-714.
16. Jamieson T, et al. (2005) The chemokine receptor D6 limits the inflammatory response in vivo. Nat Immunol 6:403-411. (Pubitemid 41716781)
17. Rajakariar R, et al. (2008) Novel biphasic role for lymphocytes revealed during resolving inflammation. Blood 111:4184-4192.
18. Morris T, et al. (2009) Effects of low-dose aspirin on acute inflammatory responses in humans. J Immunol 183:2089-2096.
19. Serhan CN, et al. (2007) Resolution of inflammation: State of the art, definitions and terms. FASEB J 21:325-332.
20. Wise H (1996) The inhibitory effect of prostaglandin E2 on rat neutrophil aggregation. J Leukoc Biol 60:480-486. (Pubitemid 26356773)
21. Takano T, Clish CB, Gronert K, Petasis N, Serhan CN (1998) Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. J Clin Invest 101: 819-826. (Pubitemid 28096079)
22. Goh J, et al. (2001) Lipoxin A(4) and aspirin-triggered 15-epi-lipoxin A(4) antagonize TNF-alpha-stimulated neutrophil-enterocyte interactions in vitro and attenuate TNF-alpha-induced chemokine release and colonocyte apoptosis in human intestinal mucosa ex vivo. J Immunol 167:2772-2780. (Pubitemid 32768909)
23. Godson C, et al. (2000) Cutting edge: Lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol 164:1663-1667. (Pubitemid 30108713)
24. Fadok VA, et al. (1998) Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 101:890-898.
25. Fang Y, Sharp GC, Yagita H, Braley-Mullen H (2008) A critical role for TRAIL in resolution of granulomatous experimental autoimmune thyroiditis. J Pathol 216: 505-513.
26. Ariel A, et al. (2006) Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat Immunol 7: 1209-1216. (Pubitemid 44594317)
27. Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA (2001) Possible new role for NF-kappaB in the resolution of inflammation. Nat Med 7:1291-1297. (Pubitemid 34007932)
28. Paul-Clark MJ, Van Cao T, Moradi-Bidhendi N, Cooper D, Gilroy DW (2004) 15-epilipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J Exp Med 200:69-78. (Pubitemid 38924729)
29. Franklin MR, Hathaway LB (2008) 2-Diethylaminoethyl-2,2-diphenylvalerate- HCl (SKF525A) revisited: Comparative cytochrome P450 inhibition in human liver microsomes by SKF525A, its metabolites, and SKF-acid and SKF-alcohol. Drug Metab Dispos 36:2539-2546.
30. Leonard MO, et al. (2002) 15-Epi-16-(para-fluorophenoxy)-lipoxin A(4)-methyl ester, a synthetic analogue of 15-epi-lipoxin A(4), is protective in experimental ischemic acute renal failure. J Am Soc Nephrol 13:1657-1662.
31. Baker N, O'Meara SJ, Scannell M, Maderna P, Godson C (2009) Lipoxin A4: Anti-inflammatory and anti-angiogenic impact on endothelial cells. J Immunol 182: 3819-3826.
32. Schwab JM, Chiang N, Arita M, Serhan CN (2007) Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447:869-874. (Pubitemid 46920139)
33. Spite M, et al. (2009) Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 461:1287-1291.
34. Taha AS, McCloskey C, Prasad R, Bezlyak V (2009) Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): A phase III, randomised, double-blind, placebo-controlled trial. Lancet 374:119-125.
35. Fiorucci S, et al.; (2002) Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology 123:1598-1606.
36. Levy BD, et al.; Severe Asthma Research Program, National Heart, Lung, and Blood Institute (2005) Diminished lipoxin biosynthesis in severe asthma. Am J Respir Crit Care Med 172:824-830.
37. Wu SH, Liao PY, Yin PL, Zhang YM, Dong L (2009) Inverse temporal changes of lipoxin A4 and leukotrienes in children with Henoch-Schönlein purpura. Prostaglandins Leukot Essent Fatty Acids 80:177-183.
38. Kowal-Bielecka O, et al. (2005) Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: An imbalance between proinflammatory and antiinflammatory lipid mediators. Arthritis Rheum 52:3783-3791. (Pubitemid 41798216)
39. Day RM, Harbord M, Forbes A, Segal AW (2001) Cantharidin blisters: A technique for investigating leukocyte trafficking and cytokine production at sites of inflammation in humans. J Immunol Methods 257:213-220.
40. Harbord MW, et al. (2006) Impaired neutrophil chemotaxis in Crohn's disease relates to reduced production of chemokines and can be augmented by granulocyte-colony stimulating factor. Aliment Pharmacol Ther 24:651-660.
41. Philippidis P, et al. (2004) Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: Antiinflammatory monocyte-macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circ Res 94:119-126. (Pubitemid 38064106)
42. Piérard-Franchimont C, Piérard GE (1988) Cantharidin-induced acantholysis. Am J Dermatopathol 10:419-423.